News & Events

Instinctif Partners Life Sciences’ Clients Shortlisted for EuropaBIO and Scrip Awards

Instinctif Partners Life Sciences’ Clients Shortlisted for EuropaBIO and Scrip Awards

17 September 2014, London, Manchester, Munich, Boston, Sydney, Melbourne: Instinctif Partners Life Science supports its clients with entries to awards and is delighted that this month its clients have been shortlisted for an number of Awards  including the EuropaBio Most Innovative Biotech 2014 Award and the 2014 Scrip Awards.

Early in September, EuropaBio, the European Association for Bioindustries, announced its “top five biotech SMEs in Europe”. The companies will compete to win the 5th annual Most Innovative EU Biotech SME Award, to be awarded during European Biotech Week (October 8) in Brussels, Belgium. The Shortlist included client Autifony, a healthcare biotech based at Imperial College London, UK, focused on the development of high value novel medicines to treat hearing disorders and serious disorders of the central nervous system, such as schizophrenia.

On the 15 September two clients – Prosensa and Roche, were represented across four categories in the announced shortlisted finalists for the 2014 10th Annual Scrip Awards. The Awards are judged by a prestigious panel of 15 independent judges, alongside Scrip Intelligence team. The winners will be announced at the black tie ceremony and dinner to be held at London's Lancaster Hotel on 3 December.

Prosensa, a biotechnology company focused on the discovery, development and commercialization of RNA-modulating therapeutics, has been shortlisted for three awards: Financing Deal of the Year, Biotech Company of the Year and Management Team of the Year. 

  • Prosensa has been shortlisted as Management Team of the Year for the second time, recognising the managements’ strategic flexibility and ability to move quickly. In just six weeks the team drove through a listing on NASDAQ, the first IPO of a European biotech company in 10 years and had to rapidly adapt to life as a public company, with operations in Europe and the bulk of investors in the USA. 
  • For the fourth time Prosensa has reached the finalist list for Biotech Company of the Year: the Company has shown a dedication and focus on developing its portfolio of exon-skipping drugs for the treatment of Duchenne muscular dystrophy (DMD), to bring hope to boys for whom DMD is a debilitating and life shortening disease.
  • The Financing Deal of the Year short listed entry recognised Prosensa’s listing in June 2013 on NASDAQ under the apposite ticker symbol RNA. The IPO was significantly over subscribed, listing at the top end of its price range and raising $89.7m, and giving it an initial market cap of $455m. This trailblazing NASDAQ IPO paved the way for other European companies to also enter the US public markets.

Roche Partnering was shortlisted for Best Partnership Alliance after forming partnership alliances with Polyphor, Discuva and Spero Therapeutics marking the company’s return to antibiotics R&D and strongly reaffirms its commitment to bringing novel therapies to patients with high unmet medical needs. The alliances combine Roche’s long standing legacy in antibiotic development and its scientific, clinical and commercial capabilities with Polyphor’s 10 years’ of research and development into macrocycle technologies, Discuva’s leading-edge technology platform and Spero’s novel virulence- and persistence-targeted approach. These collaborations hold the promise of delivering novel therapies or approaches that could tackle the increasing global challenge of antimicrobial resistance.

For further information about the EuropaBio Awards click here and for the Scrip Awards please click here.


For Further Information:

Sue Charles
Managing Partner, Life Sciences
+44 (0)20 7457 2020

back to news